BACKGROUND: Celiac disease (CD) is associated with increased rates of neuropsychiatric disease and irritable bowel syndrome, and patients may exhibit visceral hypersensitivity. AIM: The purpose of this study was to determine whether patients with CD have increased sedation requirements during endoscopic procedures. METHODS: In this retrospective cohort study, we identified CD patients undergoing either a colonoscopy or esophagogastroduodenoscopy (EGD), but not a dual procedure. CD patients were matched with control patients according to age, gender and endoscopist. For sedation requirements we defined "high" as falling outside of the 75th percentile of the entire cohort. RESULTS: In the colonoscopy analysis we identified 113 CD patients and 278 controls. In the CD group, 29 individuals (26%) required high amounts of both opioids and midazolam, as compared to 46 (17%) controls (P = 0.05). Differences were similar when considering only opioids (P = 0.06) and midazolam (P = 0.06). In the EGD analysis we identified 314 CD patients and 314 controls who met the inclusion criteria. Among the CD patients, 70 (22%) required high amounts of both opioids and midazolam compared to 51 (16%) controls (P = 0.05). Differences were similar when considering only opioids (P = 0.06) and midazolam (P = 0.04). CONCLUSIONS: Patients with CD require higher doses of sedation during upper and lower endoscopy compared to age and gender-matched controls. Putative explanations, such as visceral hypersensitivity, chronic opioid/anxiolytic use, or underlying neuropsychiatric illness, should be evaluated prospectively.
BACKGROUND:Celiac disease (CD) is associated with increased rates of neuropsychiatric disease and irritable bowel syndrome, and patients may exhibit visceral hypersensitivity. AIM: The purpose of this study was to determine whether patients with CD have increased sedation requirements during endoscopic procedures. METHODS: In this retrospective cohort study, we identified CDpatients undergoing either a colonoscopy or esophagogastroduodenoscopy (EGD), but not a dual procedure. CDpatients were matched with control patients according to age, gender and endoscopist. For sedation requirements we defined "high" as falling outside of the 75th percentile of the entire cohort. RESULTS: In the colonoscopy analysis we identified 113 CDpatients and 278 controls. In the CD group, 29 individuals (26%) required high amounts of both opioids and midazolam, as compared to 46 (17%) controls (P = 0.05). Differences were similar when considering only opioids (P = 0.06) and midazolam (P = 0.06). In the EGD analysis we identified 314 CDpatients and 314 controls who met the inclusion criteria. Among the CDpatients, 70 (22%) required high amounts of both opioids and midazolam compared to 51 (16%) controls (P = 0.05). Differences were similar when considering only opioids (P = 0.06) and midazolam (P = 0.04). CONCLUSIONS:Patients with CD require higher doses of sedation during upper and lower endoscopy compared to age and gender-matched controls. Putative explanations, such as visceral hypersensitivity, chronic opioid/anxiolytic use, or underlying neuropsychiatric illness, should be evaluated prospectively.
Authors: Vinton S Chadwick; Wangxue Chen; Dairu Shu; Barbara Paulus; Peter Bethwaite; Andy Tie; Ian Wilson Journal: Gastroenterology Date: 2002-06 Impact factor: 22.682
Authors: M Hadjivassiliou; A K Chattopadhyay; G A Davies-Jones; A Gibson; R A Grünewald; A J Lobo Journal: J Neurol Neurosurg Psychiatry Date: 1997-12 Impact factor: 10.154
Authors: Spencer D Dorn; Lincoln Hernandez; Maria T Minaya; Carolyn B Morris; Yuming Hu; Suzanne Lewis; Jane Leserman; Shrikant I Bangdiwala; Peter H R Green; Douglas A Drossman Journal: Dig Dis Sci Date: 2010-07-30 Impact factor: 3.199
Authors: M Hadjivassiliou; R A Grünewald; A K Chattopadhyay; G A Davies-Jones; A Gibson; J A Jarratt; R H Kandler; A Lobo; T Powell; C M Smith Journal: Lancet Date: 1998-11-14 Impact factor: 79.321
Authors: John K Triantafillidis; Emmanuel Merikas; Dimitrios Nikolakis; Apostolos E Papalois Journal: World J Gastroenterol Date: 2013-01-28 Impact factor: 5.742